Tonix Pharma (TNXP) has released an update.
Tonix Pharmaceuticals Holding Corp. has received FDA clearance for an Investigational New Drug application for a trial to assess its TNX-102 SL product in reducing the severity and frequency of acute stress reactions and stress-related disorders. This milestone could signal a significant advancement in treatment options for stress reaction and stress disorders, marking a potential turning point for the company and offering an exciting opportunity for investors tracking the pharmaceutical sector. The company has also updated its investor presentation, hinting at possible nonpublic information that could be of interest to stakeholders.
For further insights into TNXP stock, check out TipRanks’ Stock Analysis page.
